Inborn Errors of Metabolism (IEM) are rare disorders, with the majority having an incidence of less than 10 per 100,000 births, and a total incidence of all metabolic diseases reaching 40 per 100,000 births. The incidences of Amino Acid disorders excluding Phenylketonuria and Glycogen Storage disease are 7.6 and 2.3 per 100,000 live births respectively 1 . The incidence and the frequency of inborn error of metabolisms vary worldwide and are based on racial and ethnic structure of population. Specific genetic mutations can be more frequently seen in specific ethnicities. For instance, sickle cell anemia, caused by a genetic mutation in the HBB gene, is more common in people of African, African-American, and Mediterranean origins. Ashkenazi Jewish are also well known to host the mutation responsible for Tay-Sachs disease 2 . In other words, diseases tend to "cluster" in families because genes are passed down from ancestors to offspring. Therefore, variations in the incidence and prevalence of genetic mutations are quite different from one geographic area to another and can be partially attributed to the evolutionary factors that influence genetic variation in general. Alkaptonuria is a rare autosomal recessive disease with an incidence of 1:250,000 -1,000,000 (Table 1) . The homogentisate 1,2-dioxygenase (HGD) gene codes for the enzyme necessary to break down the homogentisic acid into maleylacetoacetic acid. This HGD gene is expressed in many organs mainly the liver, kidney, prostate, osteoarticular joints, and the gastrointestinal tract. Alkaptonuria is caused by the accumulation of homogentisic acid (HGA) in the body, with some secreted in the urine. HGA undergoes oxidation and then polymerization in connective tissues, cardiovascular, and ocular tissues, causing a bluish discoloration, an entity named as Ochronosis. Moreover, individuals with Alkaptonuria might have dark urine that turns black when exposed to air, a pathognomonic sign of this disease. Features of Alkaptonuria include increased risk of developing aortic valve and coronary artery diseases, and osteoarthritis-like damage in joints and spine. Moreover, Alkaptonuria is also classified as a secondary amyloidosis because of the deposition of serum amyloid A related to HGA ochronotic pigments; the latter was proven to be co-localized with Alkaptonuria type II Amyloids in the tissues 3,4. Pompe is a lysosomal storage disease type II. It is a rare autosomal recessive genetic disease caused by a mutation in the GAA gene responsible for the production of acid α-glucosidase (also known as acid maltase) enzyme. This enzyme breaks down glycogen into glucose in the lysozymes. Hence, deficiency in this enzyme leads to the deposition of glycogen in the body, mainly cardiac and skeletal muscles being the most severely affected. This will lead to massive vacuolar glycogen storage in almost all tissues. Three types of Pompe are present depending on the severity and the age at which the disease appears. These are known as classic infantileonset, non-classic infantile-onset, and late-onset. Severity can range from a mild slowly progressive muscle myopathy seen in adulthood period to a severe infantile-onset muscle hypotonia, weakness, and hypertrophic myopathy. So, patients experience myopathy, hypotonia, hepatomegaly, cardiomegaly, and failure to thrive. Pompe incidence is estimated to be 1:40,000 ( . Alkaptonuria and Pompe diseases are likely to occur in our geographic area (Middle East). Hence, having a single mutation in a patient is common as previously described hundreds of times in the literature. However, having more than one mutation in the same patient is an extremely rare occurrence. Human data presented in Table 1 were selected after an extensive search through PubMed and Medline. Different words were used to search for cases having combined genetic mutations in the literature, specifically in the inborn error of metabolism. "OR" and/or "AND" operators were used during the search. Only seven cases were found, including our case. Full data regarding case #4 is not available. Three out of six cases (50%) have parents with consanguineous type of marriage. Based on the incidence of Pompe disease and Alkaptonuria as depicted in Table 1 , the incidence to have both Pompe disease and Alkaptonuria at the same time is approximately 1: 10,000,000,000 -40,000,000,000. Our case is the only one reported in the literature up to our knowledge. This is a very unusual finding to have such combination of two recessive mutations.
One of the main causes of the high incidence of IEM in the Middle East is the high rates of consanguinity. In the Arab world, consanguinity includes first cousins, double first cousins, and second cousins. Consanguinity also includes individuals with at least one common ancestor as seen in tribes, endogenous marriages, and intra-communities. The main cause of high consanguinity in the Arab region is due to socio-cultural factors such as preservation of family structure and properties, ease of marriage, and better relations with in-laws. The overall consanguinity ranges from 12.8% to 80.4%. Consanguinity rate in the Lebanese population is considered low with respect to other Arab countries (12.8% -42%). This rate can be as high as 80.4% as noted in Nubia in Egypt 8 . IEMs are relatively common in our region. This is mainly due to the high rates of consanguinity as stated above. The total consanguinity can reach up to 67%, reaching 49% with first cousin consanguinity 7 . Our case has no family history of parental consanguinity. Both his parents and his sister are clinically well. One of his cousins reported to have episodes of dark urine but was not reachable. Another one died at age of 14 years after having pneumonia and hepatosplenomegaly. Having parents not consanguineous makes the probability of finding a similar case even rarer. transport sample for measuring α-glucosidase activity 9 . Moreover, Jacomelli et al validated a rapid color intensity method for semi-quantification of homogentisic acid (HGA) using a dried urine spot (DUS) paper by comparing HGA concentrations in urine and plasma to those obtained from High Performance Liquid Chromatography (HPLC). The brown color intensity obtained on the paper is proportional to HGA concentration from 1.4 mmol/L to 46 mmol/L. Such method fits very well for Alkaptonuria screening even before the detection of dark urine because of its safety, reliability, and ease of use 10 . After screening, additional confirmatory testing is necessary that include measuring enzymes activities and/or molecular analysis for gene mutations.
In our case, the patient was referred to the American University of Beirut Medical Center because of progressive motor weakness and failure to thrive at age of 6 years. His past medical history includes recurrent respiratory tract infections, greenish mucoid stools, frequent episodes of dark urine, and gastroesophageal reflux. Initial laboratory testing include a comprehensive panel for hematologic and biochemical tests in addition to urine organic acid measurements. All tests were within normal range except for creatinine phosphokinase (CPK) enzyme, plasma α-glucosidase, homogentisic acid, and urine 1,4 α-glucosidase. Demographic, clinical, and laboratory data are summarized in Table 2 . Further molecular tests for GAA and HGD genes mutations were performed. GAA sequencing revealed a 2 heterozygous mutations, the C.670>T in exon 3, and the C.1064T>C in exon 6. HGD sequencing also revealed a homozygous deletion of 649 base pairs in exon 2 and the surrounding DNA sequences in flanking introns. The patient received orfadin (nitisinone) that improved his Alkaptonuria condition by decreasing HGA. The patient was lost to follow up since 2013 where he was waiting to receive enzyme replacement therapy (ERT).
As a conclusion, occurrence of a double genetic mutations in one person is extremely rare, specifically in our case where neither the disease prevalence, nor consanguinity are in favor to have such a rare outcome. However, it should be kept in mind there the possibility of having more than one mutation in a patient is still there, especially when the clinical presentation of the patient is complex and signs and symptoms do not fit in one disease. Presence of parental consanguinity can be an additional key point to suspect such cases. Moreover, it is of utmost importance to screen neonates and pediatric patients if clinical signs and symptoms indicate the presence of IEM as soon as possible using the dried blood neonatal cards in order to prevent the outcome of such debilitating and fatal diseases.
